#RIGImmune is presenting a third presentation at #ERSCongress 2024 tomorrow! Join us to hear from PhD researcher Hugo Ombredane about his presentation, “Effects of an anti-viral interferon booster, RIG-I agonist (RIG-101), on influenza infection in vitro and in vivo.” See the full program to learn more: https://bit.ly/3YYyKXI
RIGImmune Inc.
生物技术研究
Farmington，Connecticut 558 位关注者
Targeted non-LNP Delivery of RNA Therapeutics
关于我们
RIGImmune is a platform biopharmaceutical company developing innovative RNA therapeutics delivered directly to the respiratory tract,?without lipid nanoparticle systems,?to improve the lives of patients who suffer from respiratory diseases?with high unmet medical need. ?Led by biopharma industry veteran, President Susan Sobolov, PhD, RIGImmune scientists have discovered and developed a non-LNP nano-emulsion respiratory delivery platform technology named NEED?. RIGImmune was launched in 2020 by Yale Professors Anna Marie Pyle, PhD and Akiko Iwasaki, PhD. Pyle and colleagues co-discovered RIG-I, an innate immune sensor, and a new class of oligonucleotide compounds called stem loop RNA therapeutics or “SLRs” for the selective targeting of RIG-I. Upon sensing viral RNA or tumor DNA, RIG-I stimulates the innate and adaptive immune responses by activation of the Type I interferon pathway. Iwasaki is renowned for her work with mechanisms of immune defense against viruses at the mucosal surfaces. RIGImmune is a UCONN TIP company located in Farmington, CT, and has an experienced management team of successful biotech entrepreneurs and world-renowned scientists. More information is available at: rigimmune.com.
- 网站
-
rigimmune.com
RIGImmune Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Farmington，Connecticut
- 类型
- 私人持股
地点
-
主要
获取路线
400 Farmington Avenue
US，Connecticut，Farmington，06032
RIGImmune Inc.员工
-
Daniel Wagner
Early Stage Life Science Investor and Board Member
-
Tom Smart
Chief Executive Officer, Board Member, Actym Therapeutics, Inc.
-
Jag Shur
Pioneering Biotech Innovator | Advancing Inhaled Delivery of Nucleic Acids for Precision Medicine
-
Nicole Barkley
Operations/Executive Administration
动态
-
#NEWS: #RIGImmune today announced three oral presentations demonstrating the viral prevention effects of intranasal RIG-101, our lead product development candidate, at the 2024 European Respiratory Society Congress. The three oral presentations highlight that RIG-101 has the ability to reduce viral loads by inducing innate immune responses when delivered to the respiratory tract. Read the full release: https://bit.ly/4cXhupo #drugdiscovery #innovation #ERSCongress
-
-
Don’t miss it! Dr Shyreen Hassibi, PhD, will be presenting on #RIGImmune’s RIG-101 at 2:20 p.m. CEST tomorrow at the 2024 European Respiratory Society Congress! Join us to hear her presentation about “Adjuvancy effects of a RIG-I agonist (RIG101) on H1N1 HA antigen intranasally vaccinated mice and human nasal epithelium/PBMCs co-culture.” See the full program to learn more: https://bit.ly/3YYyKXI #ERSCongress
-
-
Join us at #ERSCongress 2024 in Vienna! Today at 3:55 p.m. CEST, Leah Daly and Kazuhiro Ito, PhD, will present on the pan-antiviral effects of RIG-101. See the full program to learn more: https://bit.ly/3YYyKXI
-
-
#RIGImmune is heading to Vienna for the 2024 European Respiratory Society Congress! We’re excited to connect with peers and participate in discussions about the latest research in the respiratory field. Join us from September 7th – 11th to hear presentations about our candidate RIG-101 and its potential to reduce viral infection-related respiratory exacerbations, including asthma, COPD and other chronic respiratory diseases from Kazuhiro Ito, PhD, Dr Shyreen Hassibi, PhD, Leah Daly and Hugo Ombredane, PhD Researcher. See the full program here: https://bit.ly/3YYyKXI #ERSCongress #innovation
-
#RIGImmune is proud to be among the 260 innovators presenting at this year’s Yale Innovation Summit! Join us on May 29th at 1:30 pm to hear from our President, Susan Sobolov, about how we are delivering life-changing genetic medicines. ? We’re looking forward to presenting and supporting the #STEM field in New Haven. ? #YaleInnovation24 #NHV?
?We’re pleased to announce the 260 innovators who have been selected to pitch their breakthrough ideas and startups at the Yale Innovation Summit this month! These early-stage ventures spanning the #arts, #biotech, #climate, #health, and #tech will be featured in virtual spotlights, ePoster presentations, and five LIVE pitch presentations on May 29-30. #YaleInnovation24? MEET THE PRESENTERS ?? https://lnkd.in/erHdRzXN
-
#RIGImmune is incredibly proud that our co-founder, Akiko Iwasaki, PhD, was recognized by TIME as one of the 100 Most Influential People of 2024! ? Her expertise in immunology has provided key insights into issues like long COVID and led to the development of RIGImmune’s innovative science. ? Read more about Dr. Iwasaki below ?? ? #TIME100 #Immunology
Sterling Professor of Immunobiology at Yale University School of Medicine, Investigator of Howard Hughes Medical Institute
TIME's list of the 100 Most Influential People in the world is out. I'm honored, delighted, and grateful to be a part of this incredible group #TIME100!! TIME https://lnkd.in/eFSaNf83
Akiko Iwasaki: The 100 Most Influential People of 2024
time.com
-
RIGImmune’s mission is to create a new class of broad-spectrum antivirals with our #RNAtherapeutics and novel delivery platform, NEED?. ?NEED? is highly versatile with successful topical lung and nasal delivery along with systemic delivery of diverse nucleic acid cargo. ? #RIGImmune Board Chair Marty Driscoll joined Biohaven and Yale Ventures on January 7th at their Pre-JPM Healthcare Conference Event to present on RIGImmune’s lead candidate RIG-101 and NEED?. ? RIGImmune is also advancing a program to demonstrate the effective delivery of mRNA with NEED? against CFTR, a mutant gene associated with cystic fibrosis:?https://bit.ly/3vhNlkl ? #drugdiscovery #immunotherapeutics #JPM2024
This past weekend we partnered with Yale University, Yale Ventures and many #biotech companies, local to New Haven, CT, who shared their groundbreaking #innovations in #healthcare. This was an inspiring event that fueled our ongoing mission to deliver therapies to patients where there are unmet needs.
-
-
It’s an honor to have #RIGImmune’s Board Chair, Marty Driscoll present alongside other esteemed colleagues at the Pre-JPM Biohaven and Yale Ventures Healthcare Conference Event!? ? He’ll be speaking about our new class of #RNAtherapeutics and our novel delivery platform,? NEED?, a proprietary nano-emulsion formulation technology that has demonstrated the capability to effectively deliver nucleic acids without the need for LNP encapsulation.?? ? RIG-101, formulated with the NEED? technology and delivered by the intranasal route, is advancing through IND-enabling activities for a clinical program designed to demonstrate effective pan-viral transmission inhibition in at-risk patient populations.? ? #biotech #RNATherapeutics #JPM2024?
-
-
We’re excited to join other Yale University spinout companies for the Biohaven and Yale Ventures Healthcare Conference Event on January 7th!?#RIGImmune’s Board Chair, Marty Driscoll, will present a “New Paradigm for Respiratory RNA Delivery” focusing on our lead candidate, #RIG101, and NEED delivery platform. ? Learn more about RIGImmune’s innovative #RNATherapeutics: https://bit.ly/3vhNlkl ? #biotech #innovation #StemLoopTherapeutics #JPM2024
-